Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 14/20 | 0.53 |
| ▸ | CASP1 | P29466 | 13/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 10/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 10/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 11/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577842 | 0.83 | CTSK (0.65) | CASP3CASP1CTSKCTSL | |
| SCHEMBL6579878 | 0.82 | CTSK (0.49) | CASP3CASP1CTSKCASP6CASP8 | |
| SCHEMBL6580235 | 0.81 | CASP3 (0.46) | CASP3CASP1CTSKCASP6CASP8 | |
| SCHEMBL6580001 | 0.79 | CTSL (0.48) | CASP3CASP1CTSKCTSLCAPN1 | |
| SCHEMBL6582052 | 0.78 | SIGMAR1 (0.54) | CASP3CASP1CTSKCASP6CASP8 | |
| SCHEMBL6577900 | 0.76 | CTSK (0.66) | CTSKCTSL | |
| SCHEMBL6580271 | 0.76 | CTSK (0.66) | CTSKCTSL | |
| SCHEMBL6581038 | 0.76 | CTSK (0.73) | CTSKCTSL | |
| SCHEMBL6578205 | 0.75 | CASP1 (0.61) | CASP3CASP1CTSKCASP6CASP8 | |
| SCHEMBL6577566 | 0.75 | CTSK (0.56) | CASP3CASP1CTSKCASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | CASP3 590/4885CASP1 131/4885CTSK 1/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CASP3 171/4885CASP1 144/4885CTSK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.